Pharmafile Logo

News and Press Releases

Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized Metered-Dose Inhalers (pMDIs), Paving the Way for Regulatory Submissions

Successfully completed the TRECOS Phase III study, supporting the long-term safety of Chiesi’s carbon minimal pressurized metered dose inhaler (pMDI) platform Aiming to become the first pharmaceutical company to transition...

Category: Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: September 26, 2025

Chiesi
info@chiesi.uk.com
333 Styal Road Manchester M22 5LG United Kingdom

Chiesi partners with Wirral Primary Care Collaborative to advance early detection of undiagnosed COPD

It is estimated that up to 5,000 people are living with undiagnosed COPD on the Wirral, where prevalence is more than 40% higher than the national average COPD is a...

Category: Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025

Chiesi
info@chiesi.uk.com
333 Styal Road Manchester M22 5LG United Kingdom

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic rhinosinusitis along with...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 28, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round

Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical trials of...

Category: Drug Discovery
Posted: January 17, 2025

Owlstone Medical
breathbiopsy@owlstone.co.uk
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK

ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies

Pooled results from the BOREAS and NOTUS studies show meaningful clinical benefit with 31% reduction in exacerbations along with lung function improvement Data from these two phase 3 studies supported...

Category: Clinical Trials, Drug Delivery, Pharmaceutical
Posted: September 10, 2024

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK